Enobosarm
As of the edition of 20 October 2026, Enobosarm is a small molecule: in active development; acts on AR.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2027
- Kind
- Small molecule
- Registered trials
- 14, 5 stopped early
- Disease areas
- Cancer; Nervous system; Skin and connective tissue; Lungs and airways; Nutrition and metabolism; Pregnancy and women's health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Enobosarm.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| AR | Androgen receptor | P10275 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 10 | 5 | 1 | 4 |
| Phase 3 | 3 | 2 | 0 | 1 |
| All trials | 14 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| GTx | Lead sponsor of trials | 2007 to now |
| Havah Therapeutics | Lead sponsor of trials | 2017 to now |
| Veru | Lead sponsor of trials | 2021 to now |